Without new legislation, US FDA said that designations, which are required to receive priority review vouchers, cannot be assured if requested after July. While the window for designations formally closes at the end of September when the authorization of the program expires, the agency is telling sponsors that it needs 60 days before that to review any requests. If a product does get a designation, it would need to secure approval by 30 September 2022 to gain a priority review voucher.
Stakeholders are pushing for congressional reauthorization of the rare pediatric disease priority review voucher program before it sunsets. • Source: Illustration
Aspiring sponsors have only a few weeks left to request a rare pediatric disease designation from the US Food and Drug Administration as the related priority review voucher program nears its sunset.
The rare pediatric disease priority review voucher program will end on 1 October absent renewal by Congress
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.
Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.
